Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Lixisenatide for the treatment of type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cardiovascular effects of antidiabetic drugs

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Teduglutide for the treatment of short bowel syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Liraglutide: a new treatment for type 2 diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  4. Soluble mediators and the interaction of drugs in IBD.

    Research output: Contribution to journalJournal articleResearch

  1. The Liver-α-Cell Axis and Type 2 Diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  2. Endogenous glucose-dependent insulinotropic polypeptide exerts diverging and tissue specific in obese patients with type 2 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Gut-derived glucagon in man

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. The glucagon-like peptide-1 receptor agonist, liraglutide, does not suppress postprandial cholecystokinin in patients with type 1 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  5. The role of glucagon-like peptide 1 for the postprandial effects of metformin in type 2 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

View graph of relations
Lixisenatide (trade name Lyxumia®), a short-acting glucagon-like peptide 1 receptor (GLP-1R) agonist, was approved for the treatment of type 2 diabetes by the European Medicines Agency in early 2013. In preclinical investigations, acceptable toxicity and carcinogenicity profiles were demonstrated, as well as pancreatic beta cell-preserving actions and favorable effects on glycemic control. Following subcutaneous administration in humans, lixisenatide displays linear pharmacokinetics and an absorption-dependent elimination half-life of 2-3 hours. In clinical trials of up to 1 year duration in patients with type 2 diabetes, treatment with lixisenatide alone and in combination with insulin and various oral antidiabetics conferred significant reductions in HbA1c, fasting and postprandial plasma glucose. In direct comparison with the other GLP-1R agonists on the market (exenatide and liraglutide), lixisenatide appears to be less efficient, or at best non-inferior in terms of reducing HbA1c, fasting plasma glucose and body weight. Nevertheless, lixisenatide confers fewer adverse events than the other currently marketed GLP-1R agonists, while exhibiting a clinically valuable effect on postprandial hyperglycemia.
Original languageEnglish
JournalDrugs of Today
Volume49
Issue number9
Pages (from-to)537-53
Number of pages17
ISSN1699-3993
DOIs
Publication statusPublished - Sep 2013

    Research areas

  • Animals, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, Drug Interactions, Half-Life, Humans, Hypoglycemic Agents, Peptides

ID: 41954506